sponsored by integrity continuing education, inc. supported by an educational grant from mylan. the...

56
Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia Practice

Upload: colton-brummel

Post on 02-Apr-2015

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Sponsored by Integrity Continuing Education, Inc.

Supported by an educational grant from Mylan.

The Role of Short-acting Opioids in Current Anesthesia Practice

Page 2: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Bernadette Henrichs, PhD, CRNA

Professor & DirectorNurse Anesthesia Program

Goldfarb School of Nursing Barnes-Jewish College

St. Louis, Missouri

2

Page 3: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Overview of General Anesthesia

• Goals of general anesthesia

– Rapid induction and maintenance of optimal operating conditions

– Reduction of side effects

– Rapid emergence and recovery

• A combination of agents is used to induce and maintain general anesthesia in current practice

– IV hypnotics and sedatives

– Volatile inhalational agents

– Opioids

– Muscle relaxants

3Mandel, J. E. J Clin Anesth. 2014;26(1 Suppl):S1-7.

Page 4: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

4

Volatile Inhalation Agents for the Maintenance of General Anesthesia

• Common agents include sevoflurane (SEVO), desflurane (DES), and nitrous oxide (N2O)

• N2O with SEVO or DES provides fast, reliable recovery and lowers risk of myocardial depression

• Associated adverse events:

*May have deleterious effects in critically ill and pediatric patients; Mandel, J. E. J Clin Anesth. 2014;26(1 Suppl):S1-7.

SEVO/DES • Isolated cases of hepatotoxicity

N2O

• Nausea and vomiting• Diffusional hypoxemia • Pulmonary bleb rupture • Pneumothorax expansion• Inactivation of vitamin B12

*

Page 5: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Total Intravenous Anesthesia (TIVA)

• An alternative to the use of volatile agents for maintenance of anesthesia

• Anesthesia is produced entirely using IV anesthetics administered by target-controlled infusion or manual injection

• Short-acting opioids play a central role (though not always required for minimally stimulating procedures)

• Short-acting agents enable rapid recovery even after long infusions

5

Cole CD, et al. Neurosurgery. 2007;61(5 Suppl 2):369-377. DeConde AS, et al. Int Forum Allergy Rhinol. 2013;3(10):848-854. Lerman J, et al. Paediatr Anaesth. 2009;19(5):521-534. Mandel JE. J Clin Anesth. 2014;26(1):S1-S7. Mani V, et al. Paediatr Anaesth. 2010;20(3):211-222.

Page 6: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

IV Agents for the Induction and Maintenance of General Anesthesia

6

IV AGENT POTENTIAL ADVANTAGES POTENTIAL DISADVANTAGES

Propofol

– Good recovery profile– Short half-life– Low PONV incidence

– Bradycardia– Hypotension– Burning sensation

Etomidate

– Preferred if vasodilation and cardiac depression are contraindicated

– Adrenal insufficiency– Higher PONV incidence– Burning sensation

Ketamine

– Preferred for reactive airway patients (bronchodilatory)

– Cardiovascular stimulation – Hallucinations, vivid dreams,

delirium– Benzodiazepines can improve

but may slow emergence and recovery

Mandel, J. E. J Clin Anesth. 2014;26(1 Suppl):S1-7.

Page 7: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Clinical Comparisons of Anesthesia Techniques• TIVA compared to inhalation anesthesia (IA) in vertebral

disk surgery:– Shorter recovery times (spontaneous ventilation, extubation, eye

opening, and ability to give name and date of birth)*– Less PONV– Greater analgesic demand

• TIVA compared to IA in pediatric ENT surgery:– Lower perioperative heart rate – Less postoperative agitation

• TIVA and balanced volatile anesthesia in intracranial surgery were found to be comparable

7

*P<.05Gozdemir M, et al. Adv Ther. 2007;24(3):622-631. Grundmann U, et al. Acta Anaesthesiol Scand. 1998;42(7):845-850. Magni G, et al. J Neurosurg Anesthesiol. 2005;17(3):134-138.

Page 8: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Monitoring of Vital Signs to Assess Depth of Anesthesia

• Potential signs of intraoperative awareness/stress:– Tachycardia (rapid heart rate)

– Hypertension

– Sweating

– Lacrimation (tear production)

– Movement/grimacing

– Tachypnea (rapid breathing)

• New technologies for monitoring (EEG, BIS)– Helps to indicate the level of unconsciousness

– Does not guarantee against intraoperative awareness

8Shepherd J. Health Technology Assessment 2013;17:34.

Page 9: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Maintaining Appropriate Depth of Anesthesia

• Excessive level of anesthesia– Increases risk of postoperative nausea, vomiting, and

cognitive dysfunction

• Insufficient level of anesthesia– Places patient at risk for intraoperative awareness

– Although relatively rare, intraoperative awareness can cause depression, anxiety, and post-traumatic stress disorder

9Shepherd J. Health Technology Assessment. 2013;17:34.

Page 10: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Hemodynamic Stability During Surgery

• Hemodynamic instability can result in complications

• Hemodynamic measures are important indicators of the following:– Sufficient cardiac output

– Adequate SV; Volume status

– Organ perfusion

– Adequacy of pain control

– Depth of anesthesia

10Lendvay V, et al. J Anesthe Clinic Res. 2010;1:103.Cove ME, Pinsky MR. Best Pract Res Clin Anaesthesiol. 2012;26(4):453-462.

Page 11: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Rationale for the Use of Short-acting Opioids in General

Anesthesia

11

Page 12: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Opioid Receptors and Responseto Stimulation

12

Receptor Response

Mu-1 • Supraspinal analgesia

Mu-2

• Depression of ventilation• Cardiovascular effects• Physical dependence• Euphoria

Delta • Modulate mu receptors

Kappa• Spinal analgesia• Sedation• Miosis

Sigma• Dysphoria• Hypertonia

Page 13: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Advantages of the Use of Opioids for General Anesthesia

• Analgesia– Blunts neuroendocrine activation

• Hemodynamic stability– No direct myocardial depression

– Blunts catecholamine response to noxious stimuli

• Decreased stress response– Attenuates stress response during surgery

• Decreased need for hypnotic anesthetics– Less propofol needed

Brown EN., et al. Annu Rev Neurosci. 2011;34:601-628. Fukuda K (2010). Opioids. In RD Miller et al., eds., Miller's Anesthesia, 7th ed., pp. 2519-2700. Wilmore DW. Ann Surg. 2002;236(5):643-648.

Page 14: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Specific Benefits Associated with the Use of Short-acting Opioids

• Minimal effects of drug accumulation

• Predictable and rapid onset and offset

• Rapid patient response to titration allows close management of intraoperative status

• Potential for faster recovery time and reduced PONV

• Benefits are not generally affected by gender, age, weight, or renal/hepatic function

Wilhelm W, et al. Crit Care. 2008;12 (Suppl 3):S5. Egan TD. Curr Opin Anaesthesiol. 2000;13(4):449-455. Egan TD, et al. Anesthesiology. 1996;84(4):821-833. Minto CF, et al. Anesthesiology. 1997;86(1):10-23.

Page 15: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

15

Characteristic Alfentanil Fentanyl Remifentanil Sufentanil

µ-Opioid receptor selectivity

X X X X

No histamine release X X X X

Rapid response to titration X

Rapid, predictable offset of

opioid effects (5-10 min) X

Elimination independent of

renal or hepatic functionX

Desirable Characteristics of the µ-Opioids

Page 16: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Remifentanil Hydrolysis by Non-specific Esterases in the Blood and Tissues

N-C-CH2-CH3

C-O-CH3

Remifentanil

CH3-O-C-CH2-CH2-N

O

O

O

C-O-CH3

N-C-CH2-CH3

H-O-C-CH2-CH2-N

O

O

O

GR90291

N-C-CH2-CH3

C-O-CH3H-N

O

O

GR94219

Nonsp

ecifi

c

Este

rase

s>95% Major Metabolite

(Inactive)

Egan TD. Clin Pharmacokinet. 1995;29(2):80-94.

Page 17: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Pharmacokinetic Properties of µ-Opioids

*The time required for drug concentrations in blood or at effect site to decrease by 50%. Based on a 3-hour infusion.† Increases with increasing infusion duration due to accumulation.

Data derived from manufacturers’ labeling and Egan TD, et al. Anesthesiology. 1993;79:881-892. Egan TD, et al. Anesthesiology. 1996;84:821-833. Scott JC, et al. Anesthesiology. 1991;74:34-42.

Pharmacokinetics Alfentanil Fentanyl Remifentanil Sufentanil

Onset: blood-effect siteequilibration, mean

0.96 min 6.6 min 1.6 min 6.2 min

Organ-independentelimination

No No Yes No

Nonspecific esterasemetabolism

No No Yes No

Offset: context-sensitivehalf-time, mean*

50-55 min† >100 min† 3-6 min 30 min†

17

Page 18: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Practical Considerations:Rapid Onset

ADVANTAGES

• Rapid response to titration and bolus

• Control of anesthetic depth

• Hemodynamic stability

• Predictable plasma & receptor level

DISADVANTAGES

• Increased risk for:

– Bradycardia

– Hypotension

– Chest wall rigidity

– Apnea

Page 19: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Opioid Infusion Front-end Kinetics: Quick to Steady State

19Egan TD (in Miller & Pardo). Elsevier;2011.

Pro

port

ion

of S

tead

y-S

tate

Ce

(%)

Infusion Duration (min)

Morphine

Sufentanil

Fentanyl

Alfentanil

Remifentanil100

80

60

40

20

00 100 200 300 400 500 600

Infusion begins at time zero

Page 20: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Opioid Infusion Back-end Kinetics: Rapid Offset After Infusion

20Egan TD (in Miller & Pardo). Elsevier;2011.

Tim

e to

50%

Dec

rem

ent

in C

e (%

)

Infusion Duration (min)

Morphine

Sufentanil

Fentanyl

Alfentanil

Remifentanil

400

350

300

250

200

150

100

50

0

0 100 200 30 400 500 600

Page 21: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

0 60 120 180 240 300 360 420 4800.1

1

10

100

Mean Concentration Over Time With Short-acting Opioids

Time (min)

Mea

n C

on

cen

trat

ion

(n

g/m

L)

(n=5)0.5 mcg/kg/min

(n=6)0.05 mcg/kg/min

Discontinuation of infusion

21

Alfentanil

Remifentanil

ULTIVA [Mylan Inc.] Available at: http://www.ultiva.com/files/Ultiva-Prescribing-Info.pdf

Page 22: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Practical Considerations:Rapid Offset

ADVANTAGES

• Rapid response to titration

• Predictable emergence

• High-dose opioid technique without need for post-op ventilation

• Ideal for TIVA

DISADVANTAGES

• No residual analgesia

– Hemodynamic instability

Page 23: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Procedure-associated Variability in Opioid Pharmacodynamics

Ausems ME, et al. Anesthesiology. 1986;65:362-373.

Plasma Alfentanil (ng/mL)

100

50

00 200 400 600 800 1000

Intubation

Skin Incision

Skin Closure

Probability of No Response (%) (n=37)

Page 24: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Opioid Pharmacodynamic Variability

Ausems ME, et al. Anesthesiology. 1988;68:851-861.

Probability of No Response to Surgical Incision (%)

Plasma Alfentanil (ng/mL)

100

50

0200 400 600

Page 25: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Risks Associated with the Use of Opioids in General Anesthesia

• Respiratory depression

• Bradycardia

• Chest wall/laryngeal muscle rigidity

• PONV

• Pruritus

• Delayed emergence

• Dependency

• Potential hyperalgesia 

Bowdle TA. Drug Saf. 1998;19(3):173-189. Egan TD. Clin Pharmacokinet. 1995;29(2):80-94. Fletcher D, et al. Br J Anaesth. 2014;112(6):991-1004. Komatsu R, et al. Anaesthesia. 2007;62(12):1266-1280.

Page 26: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Choosing an Anesthetic Technique

26

Page 27: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Discussion Questions: Technique Considerations

• How do you determine which technique is most appropriate for a given patient?

• What are the primary concerns associated with each technique?

Page 28: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Impact of Inhalation vs Intravenous (IV) Administration of Agents

• Less PONV and greater patient satisfaction has been observed with the following:

– IV induction compared to inhalation induction*

– TIVA compared to an inhalation component

• Emergence and discharge for outpatients is essentially identical

• Inhalational anesthesia may be economically advantageous over TIVA 

28

*Both followed by inhalation maintenance. Kumar, G., et al. Anaesthesia. 2014. [Epub ahead of print] Joshi GP. Anesthesiol Clin North Am. 2003;21(2):263-272.

Page 29: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

The Anesthesia Technique You Use Should Be Based on Your Goals

• Balanced anesthesia with opioid and volatile agent

– Safe

– Practiced for decades

• TIVA

– Safe

– Relative newcomer to the OR

– Outpatient > inpatient

– May impact patient satisfaction

OR, Operating Room

Page 30: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Goals of Neuroanesthesia

• Hemodynamic stability without vasodilators

• Improved ability to rapidly change anesthetic depth

• Rapid recovery with early ability to assess neurologic function

• Improved SSEP monitoring with TIVA

SSEP, somatosensory evoked potential.

Page 31: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Goals of ENT

• Hemodynamic stability without vasodilators

• Decreased bleeding, improved operative conditions during nasal/sinus surgery or tonsillectomy

• Rapid awakening, rapid ability to protect airway, rapid recovery

Page 32: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #1

32

Page 33: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #1: 17-year-old Female

• Procedure: Septoplasty and sinus endoscopy

• History:– Significant history of nasal passage obstruction and

difficulty breathing– History of chronic sinusitis beginning at age 3

• Surgical history:– Tonsillectomy at age 7 related to obstructive sleep

apnea (OSA); complicated by prolonged paralysis to succinylcholine

Page 34: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #1: 17-year-old Female (cont’d)

• Comorbidities:– Asthma– Obesity– OSA with nasal obstruction

• Current medications:– Saline nasal irrigation qd– Albuterol prn

• Allergies:– Penicillin– No other known allergies

Page 35: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #1: Consideration of Patient Characteristics

• How do the patient’s characteristics influence your approach to formulating a plan for anesthesia? – OSA

– Obesity

– Asthma

– Atypical pseudocholinesterase deficiency

• Specific concerns with regard to this type of surgical procedure: May be stimulating at times but no incision to close at end of case

Page 36: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Emergence & Recovery

36

Page 37: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Short-acting Opioid Improves Time to Orientation Compared With N2O

37

Pro

po

rtio

n N

ot

Ori

ente

d

Time (min)

Infusion of remifentanil 0.085 µg/kg/min compared with

66% N2O

1.0

0.8

0.6

0.4

0.2

0.00 5 10 15 20 25

Remifentanil

Nitrous oxide

Mathews DM, et al. Anesth Analg. 2008;106:101-108.

Page 38: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

38

Comparison of the Short-acting Opioids: Impact on Patient Recovery

• Similar PONV is observed with fentanyl, remifentanil, alfentanil, and sufentanil

• Use of remifentanil vs other short-acting opioids is associated with the following:

– Faster postoperative recovery

– Less respiratory depression

– Higher postoperative analgesic requirements

– More shivering

Reviewed in: Komatsu R, et al. Anaesthesia. 2007;62(12):1266-1280.

Page 39: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #2

39

Page 40: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #2: 73-year-old Male

• Procedure: Right carotid endarterectomy

• Comorbid conditions:– Coronary artery disease– Type 1 diabetes– Hypertension– Peripheral vascular disease

• Surgical history:– Left femoral popliteal bypass at age 71– Stent inserted at age 68

Page 41: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #2: 73-year-old Male (cont’d)

• Current medications:– Lisonopril 20 mg qd– Insulin glargine 0.2 units/kg/day

• Renal evaluation:– Renal insufficiency determined by glomerular filtration rate (GFR) of

61 mls/min/1.73m2

• Vascular evaluation:– 90% occlusion of right carotid– 50% occlusion of left carotid

• Allergies:– No known allergies

Page 42: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #2: Questions for Consideration

• What considerations should be given for:– Regional vs general anesthesia?– Tracheal intubation vs laryngeal mask airway (LMA) device?

• What monitoring would you employ intraoperatively?

• Consider the patient’s medical history (HTN) and renal impairment in the anesthetic plan

• Important to consider quick emergence to assess neurological function

Page 43: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #3

43

Page 44: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #3: 42-year-old Female

• Procedure: – Multi-level laminectomy with lumbar fusion

– Intraoperative neurophysiologic monitoring (sensory evoked potentials, motor evoked potentials)

• Surgical history:– Previous back surgery to repair herniated disc 3 years ago

• Medical history:– Current smoker

• Current medications:– Naproxen sodium 500 mg bid (discontinued 10 days ago)

Page 45: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #3: Questions for Consideration

• What considerations are given for TIVA vs mixed anesthesia in this patient?

• Consider intraoperative monitoring of this patient

• Consider surgeon request for possible intraoperative wake up for neurologic examination

• Consider patient’s history of chronic pain medication

Page 46: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Intraoperative Neurophysiological Monitoring

• Main modalities: – Somatosensory evoked potentials (SSEPs)

– Motor evoked potentials (MEPs)

– Electromyography (EMGs); transcranial monitoring

• While both inhaled and intravenous agents blunt signal attainment, depression is greater with inhaled agents

46Deiner S. Semin Cardiothorac Vasc Anesth. 2010;14(1):51-53.

Page 47: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Case Study #3: Anesthetic Plan

• TIVA with propofol and fast-acting opioid infusion

• If intraoperative wake up is necessary, it will be possible

• Consider patient’s history of chronic pain medication– Give pain medicine before emergence

– IV Acetaminophen; IV NSAID; longer-acting narcotic

Page 48: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Emergence and Recovery: Considerations

• Goal is to prepare for and have a smooth transition to postoperative analgesia

• Early planning is essential with an agent with a rapid offset of action (within 5-10 minutes)

– Non-cumulative effects are beneficial during surgery, but a disadvantage postoperatively in terms of pain control

– Need to be prepared and address pain

• Risks for obstruction and for pulmonary aspiration are also important to consider

Page 49: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Propofol Emergence Data

49

DIPRIVAN (propofol) injection, emulsion [APP Pharmaceuticals, LLC]. Available at:http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee0c3437-614d-4631-a061-257f5f60c70b.

Pla

sma

Pro

pofo

l Con

cent

ratio

n(m

cg/m

L)

1.00

0.75

0.50

0.25

0.00

Minutes After End of Infusion

0 20 40 60 80

Target plasma concentration Recovery after:10-day infusion10-hour infusion1-hour infusion

Awakening

Page 50: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Postoperative Management: Analgesia

50

Page 51: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Postoperative Pain

• Postoperative pain is a significant cause of delayed discharge after ambulatory surgery

• Good pain control is important for prevention of negative outcomes:

– Tachycardia

– Hypertension

– Myocardial ischemia

– Decreased alveolar ventilation

– Poor wound healing

• Pain control must be individualized 51Vadivelu N, et al. Yale J Biol Med. 2010;83(1):11-25.

Page 52: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Options for Postoperative Pain Management

• Choice of analgesia should be a multimodal approach:

– Nonsteroidal agent administered IV or IM

– IV acetaminophen

– Major nerve block

– Local anesthetic wound infiltration

– Long-acting opioids administered 20 to 30 minutes before discontinuation of certain short-acting opioids

– Consider epidural administration of an opioid and/or local anesthetic

IM, intramuscular

Page 53: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Opioids in Postoperative Analgesia

• Give opioids prior to emergence as needed – IV Acetaminophen if not given at induction

– Ketorolac 30 mg IV ~30 min or Caldolor IV

– Dilaudid 0.2-2.0 mg IV ~ 20-30 min

– MSO4 0.1 to 0.2 mg/kg IV ~20 to 30 min

– Fentanyl 1 to 1.5 u/kg IV ~5 min

• Dose epidural if epidural placed

• Surgeon: Infiltrate with long-acting local anesthetic

• Consider continuing remifentanil 0.05 to 0.1 mcg/kg/min in PACU

Page 54: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Considerations for Special Populations

• Age; Elderly more sensitive to narcotics

• Body mass effects; Obese more sensitive to narcotics

• Comorbid conditions

• Current medications

54

Strom C, et al. Anaesthesia. 2014;69(S1):35-44. Lerman J. Eur J Anaesthesiol. 2013;30(11):645-650. Ingrande J, et al. Br J Anaesth. 2010;105 (S1):16-23. Hachenberg T, et al. Curr Opin Anaesthesiol. 2014;27(4):394-402.Licker M, et al. Int J Chron Obstruct Pulmon Dis. 2007;2(4):493-515.

Page 55: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Summary

• Opioids used in anesthesia play a critical role in minimizing surgical pain and the associated adverse effects on patient outcomes

• The pharmacokinetic profiles of newer short-acting opioids are characterized by lower drug accumulation and rapid, predictable onset and offset

• The resulting rapid response to titration of short-acting opioids enables close intraoperative management of hemodynamics, patient stress response, and depth of anesthesia

• With appropriate use, short-acting opioids have the potential to improve recovery and overall patient experience and satisfaction

55

Page 56: Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant from Mylan. The Role of Short-acting Opioids in Current Anesthesia

Thank you!